Literature DB >> 10852736

Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial.

M H Nguyen1, V L Yu, A J Morris, L McDermott, M W Wagener, L Harrell, D R Snydman.   

Abstract

There is debate regarding the correlation between in vitro susceptibility testing and clinical response to therapy for Bacteroides bacteremia. We conducted a prospective multicenter observational study of 128 patients with bacteroides bacteremia. Outcome was correlated with results of in vitro susceptibility testing of Bacteroides isolates recovered from blood and/or nonblood sites, determined with use of 3 end points: mortality at 30 days, clinical response (cure vs. failure), and microbiological response (eradication vs. persistence). The mortality rate among patients who received inactive therapy (45%) was higher than among patients who received active therapy (16%; P=.04). Clinical failure (82%) and microbiological persistence (42%) were higher for patients who received inactive therapy than for patients who received active therapy (22% and 12%, respectively; P=.0002 and.06, respectively). In vitro activity of agents directed at Bacteroides species reliably predicts outcome: the specificity was 97%, and positive predictive value was 82%. Antimicrobial susceptibility testing may be indicated for patients whose blood specimens yield Bacteroides species.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10852736     DOI: 10.1086/313805

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  51 in total

Review 1.  Current concepts in laboratory testing to guide antimicrobial therapy.

Authors:  Stephen G Jenkins; Audrey N Schuetz
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

2.  Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.

Authors:  Yangsoon Lee; Yongjung Park; Myung Sook Kim; Dongeun Yong; Seok Hoon Jeong; Kyungwon Lee; Yunsop Chong
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

3.  Clinical and Microbiologic Characteristics of Early-onset Sepsis Among Very Low Birth Weight Infants: Opportunities for Antibiotic Stewardship.

Authors:  Sagori Mukhopadhyay; Karen M Puopolo
Journal:  Pediatr Infect Dis J       Date:  2017-05       Impact factor: 2.129

Review 4.  [Antimicrobial and antimycotic therapy of intra-abdominal infections].

Authors:  P Kujath; M Hoffmann; A Rodloff
Journal:  Chirurg       Date:  2008-04       Impact factor: 0.955

5.  Prognostic factors and impact of antibiotherapy in 117 cases of anaerobic bacteraemia.

Authors:  R Robert; A Deraignac; G Le Moal; S Ragot; G Grollier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-21       Impact factor: 3.267

Review 6.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

7.  Is the incidence of anaerobic bacteremia decreasing? Analysis of 114,000 blood cultures over a ten-year period.

Authors:  Lukas Fenner; Andreas F Widmer; Clarisse Straub; Reno Frei
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

8.  Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.

Authors:  Carmen Betriu; Esther Culebras; María Gómez; Fátima López; Iciar Rodríguez-Avial; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

9.  Are incidence and epidemiology of anaerobic bacteremia really changing?

Authors:  A Vena; P Muñoz; L Alcalá; A Fernandez-Cruz; C Sanchez; M Valerio; E Bouza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-28       Impact factor: 3.267

10.  Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008-2012, northern Taiwan.

Authors:  F D Wang; C H Liao; Y T Lin; W H Sheng; P R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-15       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.